SCHEMBL6508205

SCHEMBL6508205

O=C(O)C1=CC=CC=CO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL10925085 0.98
SCHEMBL27907862 0.83
SCHEMBL1043730 0.79
SCHEMBL27873677 0.74 ALDH1A1 (0.34)
SCHEMBL694984 0.71 AKR1B1 (0.32)
Hydrochloric Acid SCHEMBL10924546 0.70 AKR1B1 (0.31)
SCHEMBL4789244 0.67
SCHEMBL5533943 0.67
SCHEMBL1426598 0.67
SCHEMBL3787492 0.66 CA2 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5242931-A Antiischemic agents and cardiovascular disorders KYOWA HAKKO KOGYO CO., LTD. (JP) 1993-09-07 US claimed
JP-2000250-A None JP disclosed
CN-119097699-A B7-H4 antibodies and methods of use thereof 奈斯科尔公司 2024-12-10 CN disclosed
CN-117177767-A Proteolytic enzyme mixtures for the treatment of psoriasis 麦迪伍德有限公司 2023-12-05 CN disclosed
CN-116600789-A Polymeric bile acid ester nanoparticles for inducing tolerance 耶鲁大学 2023-08-15 CN disclosed
CN-116348130-A Method for treating skin cancer 麦迪伍德有限公司 2023-06-27 CN disclosed
CN-116322748-A Compositions and methods for modulating FLRT 3-mediated signal transduction 奈斯科尔公司 2023-06-23 CN disclosed
CN-109863168-B Amylin analogs 西兰制药公司 2023-04-18 CN disclosed
WO-2023003497-A1 COMPOUNDS WITH LYSOSOMOTROPIC AND ANTIVIRAL ACTIVITY ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "ВАЛЕНТА-ИНТЕЛЛЕКТ" 2023-01-26 WO disclosed
CN-115298165-A Tetralin and tetrahydroquinoline compounds as HIF-2 alpha inhibitors 艾库斯生物科学有限公司 2022-11-04 CN disclosed
EP-3256468-A1 TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE Sunshine Lake Pharma Co., Ltd. (CN) 2017-12-20 EP disclosed
WO-2016127924-A1 TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2016-08-18 WO disclosed
CN-102405039-B Comprise cosmetics or skin composition and cosmetic treatment method containing the polymer of connecting group 莱雅公司 2016-06-08 CN disclosed
EP-2790511-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL Merck Sharp & Dohme Corp. (US) 2014-10-22 EP disclosed
WO-2013090271-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME CORP. (US) 2013-06-20 WO disclosed
WO-2005023799-A1 FUSED BICYCLIC CARBOXAMIDE DERIVATIVES AND METHODS OF THEIR USE ADOLOR CORPORATION (US) 2005-03-17 WO disclosed
EP-0974583-B1 PHENYLPIPERIDINE DERIVATIVES KYOWA HAKKO KOGYO KK (JP) 2002-05-29 EP disclosed
US-5756553-A Medical material and process for producing the same OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 1998-05-26 US disclosed
JP-H02250-A TRICYCLIC COMPOUND KYOWA HAKKO KOGYO CO LTD 1990-01-05 JP disclosed
EP-0188802-A2 Dibenz (b,e) oxepin derivative and antiallergic agent KYOWA HAKKO KOGYO CO., LTD. (JP) 1986-07-30 EP disclosed